Exelixis (EXEL) PT Lowered to $30 at Guggenheim, Following Clinical Business Update
Tweet
Share
E-mailGet Alerts EXEL Hot Sheet
Price: $26.63 --0%
Rating Summary:
19 Buy, 5 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 3 | Down: 4 | New: 39
Rating Summary:
19 Buy, 5 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 3 | Down: 4 | New: 39
Join SI Premium – FREE
Guggenheim analyst Michael W. Schmidt lowered the price target on Exelixis (NASDAQ: EXEL) to $30.00 (from $32.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Banco BPM SpA (BAMI:IM) (BNCZF) to Neutral
- Viridian Therapeutic (VRDN) PT Raised to $31 at Goldman Sachs
- Deutsche Bank Upgrades Legrand SA (LR:FP) (LGRDY) to Buy
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
